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Background: Human herpes virus 8 (HHV-8) is the underlying infectious cause of Kaposi sarcoma (KS) and other
proliferative diseases; that is, primary effusion lymphoma and multicentric Castleman disease. In regions with high
HHV-8 seroprevalence in the general population, KS accounts for a major burden of disease. Outside these endemic
regions, HHV-8 prevalence is high in men who have sex with men (MSM) and in migrants from endemic regions.
We aim to conduct a systematic literature review and meta-analysis in order 1) to define the global distribution of
HHV-8 seroprevalence (primary objective) and 2) to identify risk factors for HHV-8 infection, with a focus on HIV
status (secondary objective).
Methods/design: We will include observational studies reporting data on seroprevalence of HHV-8 in children and/or
adults from any region in the world. Case reports and case series as well as any studies with fewer than 50 participants
will be excluded. We will search MEDLINE, EMBASE, and relevant conference proceedings without language restriction.
Two reviewers will independently screen the identified studies and extract data on study characteristics and quality,
study population, risk factors, and reported outcomes, using a standardized form. For the primary objective we will pool
the data using a fully bayesian approach for meta-analysis, with random effects at the study level. For the secondary
objective (association of HIV and HHV-8) we aim to pool odds ratios for the association of HIV and HHV-8 using a fully
bayesian approach for meta-analysis, with random effects at the study level. Sub-group analyses and meta-regression
analyses will be used to explore sources of heterogeneity, including factors such as geographical region, calendar years
of recruitment, age, gender, ethnicity, socioeconomic status, different risk groups for sexually and parenterally transmitted
infections (MSM, sex workers, hemophiliacs, intravenous drug users), comorbidities such as organ transplantation and
malaria, test(s) used to measure HHV-8 infection, study design, and study quality.
Discussion: Using the proposed systematic review and meta-analysis, we aim to better define the global seroprevalence
of HHV-8 and its associated risk factors. This will improve the current understanding of HHV-8 epidemiology, and could
suggest measures to prevent HHV-8 infection and to reduce its associated cancer burden.
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Human herpes virus 8 (HHV-8) was first described in
1994 [1], and subsequently identified as the underly-
ing infectious cause of Kaposi sarcoma (KS) [2-5], there-
fore also called Kaposi sarcoma-associated herpes virus
(KSHV). Later, HHV-8 was also linked to other prolifer-
ative diseases, including multicentric Castleman disease
[6] and primary effusion lymphoma [7]. In 2010, HHV-8
was declared a Group 1 carcinogenic agent by the Inter-
national Agency for Research on Cancer, highlighting its* Correspondence: erohner@ispm.unibe.ch; jbohlius@ispm.unibe.ch
1Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern,
Switzerland
Full list of author information is available at the end of the article
© 2014 Rohner et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.public health significance [8]. HHV-8 shows a high level
of genetic variability, and is classified into five sub-types.
Until the advent of the HIV/AIDS epidemic, KS had oc-
curred mainly in older men of Mediterranean and Jewish
origin (classic KS) or in equatorial Africa as an endemic
form affecting middle-aged men in their fourth or fifth
decade. Although HHV-8 is necessary for KS to develop,
it is not sufficient, and other cofactors, such as immu-
nosuppression, are needed. Previous studies have shown
that immunosuppression is associated with an increased
risk of developing KS. In patients with solid organ trans-
plants, the risk of developing KS is increased by a factor
of 50 [9], and in untreated HIV-infected individuals, it is
increased by a factor of up to 20,000 [10]. Once theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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creased dramatically and the new, epidemic KS pre-
sented with a more aggressive, life-threatening clinical
course. From 1996 onwards, combination antiretroviral
therapy (cART) was used to reverse HIV-associated im-
munosuppression, leading to regression of epidemic KS
in developed countries [11], and reducing the risk of de-
veloping epidemic KS by up to 90% for those receiving
cART [12]. Despite this success, the residual risk of de-
veloping KS for HIV-infected patients starting cART is
still considerable [12]. KS remains a major public health
burden in resource-limited countries that have a high
prevalence of both HHV-8 and HIV and limited access
to cART [13,14].
HHV-8 seroprevalence varies between different geo-
graphic regions and sub-populations. For example, in
Uganda, where KS is endemic, HHV-8 seroprevalence
rates of 50% have been reported for the general population
[15,16], whereas, seroprevalence rates of 6% or lower have
been reported for the USA [17] and Switzerland [18].
Whitby et al. documented regional differences in Italy;
a low prevalence was reported for the northern part,
whereas a prevalence of 35% was detected in Sicily [19].
This is supported by earlier reports of high incidence rates
of classic KS in this region [20]. Ablashi et al. also noted
wide variation in the detection of HHV-8 antibodies in
populations in the USA, Asia, the Caribbean, and Africa
[21]. Outside HHV-8 endemic regions, high HHV-8 anti-
body prevalence has been described in men who have sex
with men (MSM) [4,5,18,22] and in migrants from African
regions [23]. There is some evidence that in these popula-
tions the prevalence of HHV-8 is increasing [24,25]. The
association between HHV-8 and HIV seropositivity, es-
pecially in heterosexual populations, is a matter of on-
going debate, with some studies showing an association
[24,26,27], whereas others do not [15,28,29]. Other risk
factors for HHV-8 infection, including lack of circumci-
sion [29], rural residency [30,31], lower socioeconomic
status [32], and malaria parasitaemia [33] have been pro-
posed, but remain controversial.
The exact routes of HHV-8 transmission are currently
unclear. Both sexual and non-sexual modes have been sug-
gested, but their relative importance may vary with HHV-8
endemicity [34]. In the USA, seroprevalence of HHV-8 is
very low in children [35], but, as described above, substan-
tially elevated in certain adult sub-populations such as
MSM. In this setting, it is associated with a higher number
of sexual partners and a history of previously acquired
sexually transmitted diseases (STDs) [4]. By contrast, stud-
ies from HHV-8 endemic African countries have revealed
a high HHV-8 seroprevalence in infants, indicating hori-
zontal transmission of HHV-8 between parents and chil-
dren and between siblings in these regions [16,36-38]. The
highest levels of HHV-8 shedding are found in saliva[39,40]. Thus, saliva could serve as a medium for HHV-8
transmission, compatible with both sexual and non-sexual
pathways.
Two important limitations to the comparability of the
HHV-8 seroepidemiological studies conducted to date are
the differences in the types of populations studied and the
sensitivity and specificity of the serological tests used [3,41].
The populations studied include both selected high-risk
groups, such as commercial sex workers, patients attending
STD clinics, and miners, as well as members of the general
population. With respect to HHV-8 testing, there are vari-
ous immunofluorescence assays (IFAs) and enzyme-linked
immunoassays (EIAs) available, which detect antibodies
that are expressed during the latent phase or the lytic cycle
of the infection. Although inter-assay correlation is less of
an issue in sera with high titers of virus antibodies (for ex-
ample, sera from patients with KS), results tend to differ in
sera from low-risk groups, such as blood donors [41].
To date, one systematic review and meta-analysis has
been conducted on the prevalence of HHV-8 and the as-
sociation of HIV in China. Zhang et al. documented a
considerable variation in HHV-8 seroprevalence in dif-
ferent geographical sub-regions and ethnic groups, and a
threefold increased risk for HHV-8 seropositivity in
HIV-infected compared with HIV-uninfected individuals
[42]. However, the review was restricted to China, and
has methodological limitations; for example, study qual-
ity and differences in the characteristics of the HHV-8
tests used were not considered in the analysis.
Our systematic review and meta-analysis will build an
important basis for ongoing and future research on
HHV-8 and KS. The ultimate goal is to contribute to the
development of measures to prevent HHV-8 infection
and reduce its associated cancer burden.
Aims and objectives
We aim to conduct a systematic literature review and
meta-analysis to define the global distribution of HHV-8
seroprevalence. We will identify risk factors for HHV-8
infection with a focus on HIV status, and describe
changes in HHV-8 seroprevalence over time.
The primary objective is to describe the prevalence of
HHV-8 in children and adults stratified by geographical re-
gion, age, gender, ethnicity, HIV status, sexual orientation,
and calendar year. The secondary objective is to determine
the association between HIV and HHV-8 seropositivity in
children and adults stratified by geographical region, differ-
ent risk groups, and calendar year.
Hypotheses for the analytical part
We will investigate the following three hypotheses: 1) the
seroprevalence of HHV-8 will be higher in HIV-infected
than in HIV-uninfected individuals; 2) the difference in
HHV-8 seroprevalence between populations from HHV-8
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uninfected indviduals but small for HIV-infected individ-
uals; and 3) outside HHV-8 endemic regions, the HHV-8
seroprevalence will have increased over calendar years in
high-risk groups such as MSM and HIV-infected individ-
uals, but not in low-risk groups, such as the HIV-
uninfected general population and blood donors.
Methods/design
We will conduct a systematic literature review and meta-
analyses using state of the art methods [43]. Reporting will
be in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statement [44].
Study eligibility
Primary objective
We will include studies reporting data on the seropreva-
lence of HHV-8 in populations from any region in the
world. Studies measuring HHV-8 DNA only and not
HHV-8 antibodies are not eligible. Populations with dif-
ferent risk profiles for HHV-8 infection will be included
without restriction. Data for all age groups will be in-
cluded. We will include cross-sectional, cohort and
case–control studies, as well as clinical trials document-
ing the seroprevalence of HHV-8 with a minimum sam-
ple size of 50 analyzed participants in total. Case reports
and case series will be excluded. We will primarily seek
to include population-based studies, but will also include
hospital-based studies. We will include full text publica-
tions, but will also assess studies published only as ab-
stracts. Clinical and methodological differences between
studies will be assessed in subgroup analyses and meta-
regressions (see Statistical analysis section).
Secondary objective
The same criteria as detailed above will apply, but we
will include only studies that report the prevalence and
association of HIV and HHV-8 in HIV-infected and
HIV-uninfected individuals sampled from the same
source population and tested for HHV-8 antibodies
using the same test. Single-arm studies in which HHV-8
seroprevalence has been measured either in HIV-
infected or in HIV-uninfected individuals only will be
excluded.
Search strategy for identification of relevant studies
Electronic searches
Preliminary electronic literature searches for relevant
studies have already been conducted in December 2012.
We searched MEDLINE and EMBASE without language
restrictions for published reports from 1994 to 2012. An
update of the literature search will be conducted in2014. All literature searches are restricted to studies in
humans. The following search strategies are being used.
MEDLINE search strategy using PubMed
The search terms are: ((((((prevalen* OR inciden* OR epi-
demiolog* OR seroprevalen* OR sero-prevalen* OR seroe-
pidemiolog* OR sero-epidemiolog* OR seropositiv* OR
sero-positiv*)) OR ((((seroepidemiologic studies[MeSH
Terms]) OR prevalence[MeSH Terms]) OR incidence
[MeSH Terms])))) AND (((((((((((((herpesvirus 8, human
[MeSH Terms]) OR “human herpesvirus 8”) OR “hhv-8”)
OR “hhv8”) OR “kshv”) OR “kaposi sarcoma associated
herpesvirus”) OR “kaposi’s sarcoma associated herpes-
virus”) OR “kaposi sarcoma-associated herpesvirus”) OR
“kaposi’s sarcoma-associated herpesvirus”) OR “kaposi sar-
coma herpesvirus”) OR kaposi virus))))) NOT ((animals
[mh] NOT humans[mh])).
EMBASE search strategy using science direct
The search terms are as follows:
#1.1 “human herpesvirus 8”/exp OR “human
herpesvirus 8” OR “hhv-8” OR “hhv8” OR “kshv” OR
“kaposi sarcoma associated herpesvirus”/exp OR
“kaposi sarcoma associated herpesvirus” OR “kaposi
sarcoma-associated herpesvirus”/exp OR “kaposi
sarcoma-associated herpesvirus” OR kaposi NEXT/3
herpesvirus OR kaposi NEXT/3 virus AND [embase]/lim
#1.2 “prevalence”/exp OR prevalence OR
“seroprevalence”/exp OR seroprevalence OR
“incidence”/exp OR incidence OR “seroepidemiology”/
exp OR seroepidemiology AND [embase]/lim
#1.3 prevalen* OR inciden* OR epidemiolog* OR
sero*epidemiolog* OR sero*prevalen* OR sero*positiv*
AND [embase]/lim
#1.4 #1.2 OR #1.3
#1.5 #1.1 AND #1.4
#1.6 “animals”/exp NOT “humans”/exp
#1.7 #1.5 NOT #1.6
Searching other sources
We will also contact experts in the field to identify add-
itional and unpublished studies. We will screen reference
lists of relevant papers and search the following conferences:
 Annual Meeting of the American Society of Clinical
Oncology (ASCO) (http://www.asco.org/ASCOv2/
Meetings);
 International Conference on Malignancies in AIDS
and Other Acquired Immunodeficiencies (http://
www.capconcorp.com/meeting/2013/14thICMAOI/
index.asp);
 Conference on Retroviruses and Opportunistic
Infections (CROI) (www.croi2014.org).
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Two reviewers will independently screen the study refer-
ences identified through the literature search for the eligibil-
ity criteria stated previously. If eligibility cannot be assessed
from the title and abstract, we will obtain a full version for
assessment. Studies that appear to meet the inclusion cri-
teria in the initial screening will be further assessed by scru-
tinizing the full text reports and publications. If there is
insufficient information to judge eligibility, the principal in-
vestigator of the study will be contacted for clarification.
Any disagreement between the two reviewers will be re-
solved by discussion. All steps of the literature search will
be documented and illustrated in a flow diagram.
Data extraction
Two reviewers will use a standardized and piloted form to
extract data on study characteristics, study population, ex-
posures, risk factors, and reported outcomes. Study charac-
teristics will include the study design and quality, calendar
year of sample collection, geographical location, study
population, and setting. Data on study population and set-
ting will include country, location of household (rural ver-
sus urban), age, gender, ethnicity, socioeconomic status
(for example, number of household members, crowding,
water source, shared toilet), sexuality (sexual orientation,
sexual practices, past STDs, circumcision), HIV status and
use of cART, different risk groups for sexually and paren-
terally transmitted diseases (MSM, sex workers, hemophil-
iacs, intravenous drug users (IDUs)), other causes of
immunosuppression (for example, solid organ transplant-
ation), and other comorbidities such as malaria. We will
also document the type of sample tested (serum, plasma,
whole blood, other) and the characteristics of the test used
to determine HHV-8 seropositivity, including sensitivity,
specificity, type of test (IFA, EIA) and antigens used (latent
(for example, ORF73/LANA), lytic (for example, ORF65,
K8.1, ORF26)). We will extract crude data on prevalence of
HHV-8 in different populations with 95% confidence inter-
val (CI), and on factors used for stratifications and adjust-
ments. To evaluate the association of HIV and HHV-8, we
will extract the prevalence of HHV-8 in HIV-infected and
HIV-uninfected populations and, if available, crude and
confounder-adjusted odds ratios (ORs) with 95% CI. Fac-
tors used for adjustment will be recorded. Data will be en-
tered into an electronic database to be developed for this
project. Data entries of the two reviewers will be compared
and revised until consensus is reached. If data are not re-
ported for relevant risk strata, the study authors will be
contacted and asked to provide additional information.
The effect of missing data will be assessed.
Quality assessment
In compliance with the National Institute for Health
and Clinical Excellence (NICE) [45] and Grading ofRecommendations Assessment, Development, and Evalu-
ation (GRADE) [46] guidelines, we will use the criteria
listed below to assess risks of bias in observational studies.
The effect of these criteria on the overall results will be
tested individually; we will not use quality scores because
these themselves tend to introduce bias [47]. Because
many risk factors for HHV-8 seropositivity have been de-
scribed, which may act as potential confounders, it is par-
ticularly important to assess whether the outcomes of
interest have been adjusted or stratified for relevant con-
founders.
Quality assessment
Quality assessment will assess the following factors:
1. Study design
a. Study type (cross-sectional study, cohort study,
and for the secondary objective, case–control
study also).
b. Whether the study design was retrospective
or prospective.
2. Research question
a. For the primary objective: whether HHV-8 prevalence
was the primary outcome of the study.
b. For the secondary objective: whether the
association between HIV and HHV-8 was the
primary outcome of the study.
3. Selection of participants / eligibility criteria
a. Whether the sampling method allowed for a
representative sample of the source population
b. Whether inclusion and exclusion criteria
were appropriate.
c. Whether participants’ characteristics and
exposures with a potential influence on HHV-8
seropositivity were assessed.
d. Whether comparisons are presented between
participants and non-participants and whether
these were similar.
Additionally for the secondary objective:
e. Whether comparability of the HIV-infected and
HIV-uninfected group in terms of relevant con-
founders and effect modifiers was assessed.
f. Whether inclusion and exclusion criteria were the
same for HIV-infected and HIV-uninfected
people.
4. Measurement of exposures and outcome
a. Whether the test used to assess HHV-8 seroposi-
tivity is regarded as valid (the following tests are
regarded as valid: IFA, EIA).
b. Whether methods to ascertain participants’
characteristics and exposures were both valid and
reliable.
Additionally for the secondary objective:
Rohner et al. Systematic Reviews 2014, 3:11 Page 5 of 7
http://www.systematicreviewsjournal.com/content/3/1/11c. Whether the same sample (serum, plasma, whole
blood, other) was tested in both the HIV-infected
group and the HIV-uninfected group.
d. Whether outcome assessors were blinded to the
HIV status of the participants.
e. Whether methods to measure potential
confounding factors and effect modifiers were
both valid and reliable.
5. Control of confounding and interaction (for the
secondary objective only).
a. Whether outcomes were adjusted or stratified for
relevant confounders.
6. Appropriateness of analytical methods.
a. Whether the statistical method used was
appropriate for the outcome data.
b. Whether ≥ 80% of the people included had their
samples analyzed.
c. Whether comparisons between individuals who
had their sample analyzed and indviduals who
dropped out of the study are presented, and
whether they were similar.
Statistical analysis
For the primary objective (prevalence of HHV-8) we aim
to pool data on HHV-8 prevalence using a fully bayesian
approach for meta-analysis with random effects at the
study level [48]. For every estimate of HHV-8 prevalence
in the meta-analysis, the number of HHV-8 positive in-
dividuals out of all tested individuals will be assumed to
follow a binominal distribution with unknown under-
lying risk, p. We will model the baseline log odds of
HHV-8 seropositivity (that is logit(p) as a normal ran-
dom variable drawn from a common normal distribu-
tion) with the mean equal to the baseline log odds in the
population of possible studies, and variance representing
the variability between studies. We expect moderate to
high statistical heterogeneity between studies. Therefore,
we aim at exploring differences in prevalence between
studies in sub-group analyses, and if feasible, in random-
effects meta-regression. Depending on the degree and
nature of heterogeneity identified, we might not present
a single overall pooled estimate, but rather provide sub-
group estimates.
We will explore the following factors that might ex-
plain between-study heterogeneity: geographic location
of the study, rural versus urban sites, calendar years of
recruitment, age, gender, ethnicity, HIV status, different
risk groups for sexually and parenterally transmitted in-
fections (MSM, sex workers, hemophiliacs, IDUs), other
reasons for immunosuppression (such as solid organ
transplantation), study design and size, study quality,
and type of HHV-8 test used. Based on epidemiological
and biological reasoning, we will assess a limited number
of these factors in random-effects meta-regression. Sub-group specific prevalence estimates are required for
these analyses. These might be available both within and
between studies. Depending on the available number of
studies, we will account for this in the analysis by intro-
ducing additional random effects.
We expect that different HHV-8 tests have been used
across the identified studies. It is known that these tests
perform differently in terms of sensitivity and specificity
[49-51]. We will perform meta-regression analysis to ex-
plore the relationship between test performance charac-
teristics and prevalence. As a sensitivity analysis, we will
also perform standard random-effects logistic regression
analysis for all analyses mentioned above. HHV-8 preva-
lence rates will be presented as geographical maps. Indi-
vidual study estimates will be presented as proportions
with 95% Wilson score CI. For pooled estimates, propor-
tions will be accompanied by 95% credibility interval
(CrI) and 95% prediction interval (PI). The PI can be
interpreted as the range of likely estimates for future
studies, and it also reflects between-study heterogeneity.
For the secondary objective (association of HIV and
HHV-8) we aim to pool ORs for the association of HIV and
HHV-8 using a fully bayesian approach for meta-analysis
with random effects at the study level [48]. As a sensitivity
analysis or in cases where a bayesian approach is not feas-
ible, we will perform standard random-effects logistic re-
gression analyses. To address confounding we will pool
crude ORs as well as adjusted ORs (if reported). The fol-
lowing factors will be considered as potential confounders
and sources of bias at study level: age, gender, ethnicity,
sexuality (sexual orientation, sexual practices, past STDs,
circumcision), different risk groups for sexually and paren-
terally transmitted infections (MSM, sex workers, hemo-
philiacs, IDUs), socioeconomic status (for example, number
of household members, crowding, water source, shared toi-
let), location of household (urban, rural), cART use, other
causes of immunosuppression (for example, solid organ
transplantation) and comorbidities such as malaria. We will
explore sources of heterogeneity between studies with pre-
specified sub-group analyses and determine differences be-
tween sub-groups with meta-regression. The following
factors will be considered: geographic location of study, cal-
endar years of recruitment, age, gender, ethnicity, use of
cART, sexual orientation, different risk groups for sexually
and parenterally transmitted infections (MSM, sex workers,
hemophiliacs, IDUs), study design and size, study quality
and type of HHV-8 test used. Individual study estimates
will be presented as ORs accompanied by standard 95% CI.
For pooled estimates, ORs will be accompanied by 95% CrI
as well as PI.
Continuous covariates will be modeled using fractional
polynomials, with a maximum of two power terms. Se-
lection of power terms will be based on the deviance. All
bayesian analyses will be performed using WinBUGS
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weakly informative prior distributions will be used. In
many situations, the available data make it difficult to es-
timate the between-study heterogeneity that is captured
by the standard deviation, τ [52,53]. Thus, the results for
the posterior distribution of τ can be sensitive to the
choice of the prior distribution for τ. We therefore will
conduct sensitivity analyses with different choices for
the prior distributions of τ. The required burn-in will be
determined using three chains and subsequent plots of
the Brooks-Gelman-Rubin statistics and auto-correlation
plots [54]. We plan to use 50,000 iterations as posterior
distribution, but the final decision will be based on the
size of the Monte Carlo error (< 0.001). All standard
random-effects analyses and data management will be
performed using Stata v.12.1 (StataCorp, College Station,
TX, USA); maps will be realized in ArcGIS v.10.Discussion
Since the first description of KSHV (or HHV-8) almost
20 years ago, many studies using different tests have
been conducted to measure its seroprevalence in differ-
ent populations, to identify risk factors for HHV-8 infec-
tion, and to investigate possible routes of transmission.
Overall, the results of these studies have created a puz-
zling picture without clear recommendations on the pri-
mary prevention of HHV-8 infections.
Therefore, we believe that a systematic review and
meta-analysis of the existing studies, taking into account
the differences in study design and conduct, is needed.
We aim to describe the global distribution of HHV-8
seroprevalence and its associated risk factors. This will
provide a valuable basis for ongoing and future research
on this topic, and also help to identify research gaps.
Until effective and affordable vaccines against HHV-8
become available [55], preventive measures against the
spread of this oncogenic virus are needed. The ultimate
objective of the project is to contribute to the develop-
ment of such preventive measures in order to reduce the
cancer burden caused by HHV-8 infection.
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